Halobetasol Propionate

丙酸乌倍他索

Report date: 2026/04/08 20:02:35
NME

Base Information

Drug NameHalobetasol Propionate
Drug Alias NameUlobetasol propionate卤倍他索丙酸酯丙酯卤倍他素卤贝他索丙酸酯Ultravate +[10] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionCytosolic phospholipase A2 agonistsGlucocorticoid receptor agonists
TargetsGlucocorticoid receptorCytosolic phospholipase A2
Therapy Area/IndicationsPlaque psoriasisPsoriasisPruritus +[6] 
Global Approved IndicationsSkin Diseases
Approved Indications in ChinaSkin Diseases
Original Approved Country/TerritoryUnited States
Original Approved Date1990/12/17
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSun Pharmaceutical Industries LtdNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesBright Future Pharmaceutical Laboratories Ltd
Inactive CompaniesTherapeutics IncActavis IncSun Pharmaceutical Industries Inc +[6] 
Active IndicationsPsoriasisSkin Diseases
Inactive IndicationsPlaque psoriasisPruritusDermatitis +[4] 

Other Information

ATC CodeD07AC21
Related LinksWikipediaDrugBankKEGG